EVALUASI OUTCOME KLINIK REGIMEN KEMOTERAPI BERBASIS CISPLATIN TERHADAP PASIEN KANKER SERVIKS
Abstract
Keywords
Full Text:
PDFReferences
Amanagapa, G. (2015). Insidensi dan Gambaran Penderita Kanker Serviks di RSUP Dr. Hasan Sadikin
Bandung Tahun 2014. Tesis (abstrak), Fakultas Kedokteran Universitas Kristen Maranatha Bandung.
Tersedia: http://repository.maranatha.edu. [18 Agustus 2016]
Friyadi, M. H. Askandar, B. (2014). Perbandingan Operabilitas setelah Pemberian Kemoterapi
Neoadjuvant Cisplatin dan Paclitaxel-Carboplatin pada Kanker Serviks IIB di Divisi Ginekologi
Onkologi RSUD Dr. Soetomo, Majalah Obstet Ginekol Indonesia, 22(1). 13-21
Gonzalez, A. D., Graniel, C.L., Enciso, A.G., Revira, R., I. Mariscal, I., Montalvo, G., Gomez, E., de La
Garza, G., Chanona, G., Mohar, A. (2003). A Phase II Study of Multimodality Treatment for Locally
Advanced Cervical Cancer: Neoadjuvant Carboplatin and Paclitaxel Followed by Radical
Histerectomy and Adjuvant Cisplatin Chemoradiation. Annals of Oncology, 14:1278-84.
Komite Nasional Penanganan Kanker (KPKN). (2015). Panduan Pelayanan Klinis Kanker Serviks.
Jakarta: Kementerian Kesehatan Republik Indonesia. 1-5.
Lyle, J. (2000). ‘Cervical Cancer’ in Herfindal, E.T. and Gourley, D.R. (Ed.), Textbook of Therapeutics
Drug and Disease Management, 7th ed., Lippincott Williams and Wilkins, Philadelphia. 1907-1911.
National Comprehensive Cancer Network (NCCN). (2013). NCCN Clinical Practice Guidelines in
Oncology Cervical Cancer version 2.2063.MS-7
Rasjidi, I. (2007). Epidemiologi Kanker Serviks. IJoC, 3(3):103-8.
Sirait, A.M., Soetiarto, F., Oemiati, R. (2003). Ketahanan Hidup Penderita Kanker Serviks di Rumah
Sakit Kanker Dharmais, Jakarta, Bul Penel Kesehatan,31(1): 13-24.
Verhulst, A.L.J., Savelberg, H.H.C.M., Vreugdenhil, G., Mischi, M., Schep, G. (2015). Whole-Body
Vibration as a Modality for Rehabilitation of Peripheral Neuropathies: Implications for Cancer
Survivors suffering from Chemotherapy-Induced Peripheral Neuropathy. Oncol Rev, 9:263.